Supplementary

4-Phenethylthio-2-phenylpyrazolo[1,5-*a*][1,3,5]triazin-7(6*H*)-one

Sergey A. Smolnikov [1], Ekaterina V. Gorgopina [2], Vera R. Lezhnyova [2], Gwyneth En-Tian Ong [3], Wai-Keung Chui [3] and Anton V. Dolzhenko [4,5,*]

[1] Department of Pharmacognosy, Perm State Pharmaceutical Academy, 2 Polevaya Street, Perm, 614081, Russia
[2] Department of General and Organic Chemistry, Perm State Pharmaceutical Academy, 2 Polevaya Street, Perm, 614081, Russia
[3] Department of Pharmacy, Faculty of Science, National University of Singapore, 18 Science Drive 4, Singapore 117543, Singapore
[4] School of Pharmacy, Curtin Health Innovation Research Institute, Faculty of Health Sciences, Curtin University, GPO Box U1987, Perth, Western Australia 6845, Australia
[5] School of Pharmacy, Monash University Malaysia, Jalan Lagoon Selatan, Bandar Sunway, Selangor Darul Ehsan 47500, Malaysia
* Correspondence: anton.dolzhenko@monash.edu; Tel: +60-3-5514-5867



Figure S1: ^{1}H NMR spectrum of 4-(phenylethylthio)-2-phenylpyrazolo[1,5-*a*][1,3,5]triazin-7(6*H*)-one in DMSO-d_6.



Figure S2: ^{13}C NMR spectrum of 4-(phenylethylthio)-2-phenylpyrazolo[1,5-*a*][1,3,5]triazin-7(6*H*)-one in DMSO-d_6.



Figure S3: DEPT135 spectrum of 4-(phenylethylthio)-2-phenylpyrazolo[1,5-*a*][1,3,5]triazin-7(6*H*)-one in DMSO-d_6.